The invention discloses an antineoplastic compound DCZ0415, which has a structural formula as shown below. The invention further provides a preparation method of the compound. The method has the advantages of simple steps and high yield. Cell experiments show that DCZ0415 has killing activity to multiple myeloma cells of a person; animal experiments show that the DCZ0415 can be used for effectively inhibiting the multiple myeloma of a naked mouse from growth; research results of a mechanism of action show that TRIP13 is the target protein of DCZ0415. The compound disclosed by the invention cantarget gene or protein of a thyroid hormone receptor interactor 13 to inhibit cancer cells from proliferation to achieve the purpose of preventing and treating tumors. The compound can serve as a TRIP13 inhibitor and be used for preparing a medicine specific to TRIP13 high expression tumors. The invention provides the new treatment medicine for the multiple myeloma and the like, and further provides a new approach to overcoming the drug resistance of the disease. (The formula is shown in the description.).